Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
K. Evert,
T. Dienemann,
C. Brochhausen,
D. Lunz,
M. Lubnow,
M. Ritzka,
F. Keil,
M. Trummer,
A. Scheiter,
B. Salzberger and
others,
"Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation",
Virchows Arch,
pp. 1-12,
2021.
| DOI: | 10.1007/s00428-020-03014-0 |
P. Arora and
et al,
"B.1.617.2 enters and fuses lung cells with increased efficiency and evades antibodies induced by infection and vaccination",
Cell Reports,
pp. 109825,
2021.
| DOI: | 10.1016/j.celrep.2021.109825 |
C. Bartenschlager,
C. Römmele and
S. Temizel,
"Befragung zum Besuchsmanagement: Wie Pflegeeinrichtungen Besuche während der COVID-19-Pandemie organisierten. Protzenziale digitaler Systeme kaum genutzt",
CAREkonkret,
vol. 32/33,
2021.
| Datei: | https://opus.bibliothek.uni-augsburg.de/opus4/88555 |
S. Kumar,
D. Çalışkan,
J. Janowski,
A. Faist,
B. Conrad and
e. a. Lange,
"Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics",
Front Immunol,
vol. 12,
pp. 752227,
2021.
S. Traxler,
M. Schindler,
H. Bösmüller and
K. Klingel,
"Biologie und Pathologie von Coronaviren [Biology and pathology of coronaviruses]",
Pathologe,
vol. 42,
no. 2,
pp. 149-154,
2021.
J. Swoboda,
D. Wittschieber,
J. Sanft,
S. Kleemann,
S. Elschner,
H. Ihle,
M. Hubig,
M. Pletz,
G. Mall and
N. Gassler,
"Bone marrow haemophagocytosis indicates severe infection with severe acute respiratory syndrome coronavirus 2",
Histopathology,
vol. 78,
no. 5,
pp. 727-737,
Apr.
2021.
| DOI: | 10.1111/his.14281 |
J. Burns,
A. Movsisyan,
E. Rehfuess and
J. Stratil,
"Border control and SARS-CoV-2: an opportunity for generating highly policy-relevant, real-world evidence",
Journal of Travel Medicine,
pp. 1—3,
2021.
| DOI: | 10.1093/jtm/taab037 |
V. Priesemann,
M. M. Brinkmann,
S. Ciesek,
S. Cuschieri,
T. Czypionka,
G. Giordano,
C. Hanson,
N. Hens,
E. Iftekhar,
P. Klimek,
M. Kretzschmar,
A. Peichl,
M. Perc,
F. Sannino,
E. Schernhammer,
A. Schmidt,
A. Staines and
E. Szczurek,
"Call for a pan-European COVID-19 response must be comprehensive – Authors‘ reply",
The Lancet,
vol. 397,
no. 10284,
pp. 1541,
2021.
| DOI: | 10.1016/S0140-6736(21)00462-1 |
V. Priesemann,
M. M. Brinkmann,
S. Ciesek,
S. Cuschieri,
T. Czypionka,
G. Giordano,
D. Gurdasani,
C. Hanson,
N. Hens,
E. Iftekhar,
M. Kelly-Irving,
P. Klimek,
M. Kretzschmar,
A. Peichl,
M. Perc,
F. Sannino,
E. Schernhammer,
A. Schmidt,
A. Staines and
E. Szczurek,
"Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections",
The Lancet,
vol. 397,
no. 10269,
pp. 92—93,
2021.
| DOI: | 10.1016/S0140-6736(20)32625-8 |
H. Bräuninger,
B. Stoffers,
A. Fitzek and
et al,
"Cardiac SARS-CoV-2 infection is associated with pro-inflammatory transcriptomic alterations within the heart",
Cardiovasc Res,
pp. cvab322,
2021.
| DOI: | 10.1093/cvr/cvab322 |
J. Doehn,
C. Tabeling,
R. Biesen,
J. Saccomanno,
E. Madlung,
E. Pappe,
F. Gabriel,
F. Kurth,
C. Meisel,
V. Corman and
others,
"CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity",
Infection,
vol. 49,
no. 4,
pp. 757—762,
2021.
| DOI: | 10.1007/s15010-021-01606-9 |
J. Doehn,
C. Tabeling,
R. Biesen,
J. Saccomanno,
E. Madlung,
E. Pappe,
F. Gabriel,
F. Kurth,
C. Meisel,
V. M. Corman,
L. G. Hanitsch,
S. Treskatsch,
K. Heim,
M. S. Stegemann,
C. Ruwwe-Glösenkamp,
H. C. Müller-Redetzky,
A. Uhrig,
R. Somasundaram,
C. Spies,
H. Bernuth,
J. Hofmann,
C. Drosten,
N. Suttorp,
M. Witzenrath,
L. E. Sander and
R. Hübner,
"CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity.",
Infection.2021;49(4):757-762,
2021.
B. Lorenz-Depiereux,
J. J. Vehreschild,
M. Stecher,
L. Pilgram,
M. Witzenrath,
C. Pley,
C. Thibeault,
S. Schreiber,
T. Bahmer,
L. Fiedler-Lacombe,
A. Blumentritt,
M. Stahl,
W. Hoffmann,
S. Hanß,
D. Krefting,
C. Schäfer,
M. Nauck,
J. Schaller,
M. Hoffmann,
M. Kraus and
On Behalf Of The Napkon Study Group,
"Challenges for Ethics coordination in a large Cohort Network – experiences in the German National Pandemic Cohort Network NAPKON.",
Kongress European Biobank Week 2021,
2021.
A. Walker,
T. Houwaart,
P. Finzer and
et al,
"Characterization of SARS-CoV-2 genetic structure and infection clusters in a large German city based on integrated genomic surveillance, outbreak analysis, and contact tracing",
Epidemiology,
2021.
| DOI: | 10.1101/2021.02.13.21251678 |
| Datei: | https://doi.org/10.1101/2021.02.13.21251678 |
A. Walker,
T. Houwaart,
P. Finzer and
et al,
"Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection clusters based on integrated genomic surveillance, outbreak analysis and contact tracing in an urban setting",
Clin Infect Dis,
vol. 74,
no. 6,
2021.
| DOI: | 10.1093/cid/ciab588 |
J. Ankerhold,
S. Giese,
P. Kolb and
et al,
"Circulating multimeric immune complexes drive immunopathology in COVID-19",
Immunology,
2021.
| DOI: | 10.1101/2021.06.25.449893 |
C. Thibeault and
et al,
"Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study",
Infection,
2021.
| DOI: | 10.1007/s15010-021-01594-w |
C. Thibeault,
B. Mühlemann,
E. Helbig,
M. Mittermaier,
T. Lingscheid,
P. Tober-Lau,
L. Meyer-Arndt,
L. Meiners,
P. Stubbemann,
S. Haenel and
others,
"Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study",
Infection,
vol. 49,
no. 4,
pp. 703—714,
2021.
| DOI: | 10.1007/s15010-021-01594-w |
A. Mikolajewska,
A. Fischer,
V. Piechotta,
A. Mueller,
M. Metzendorf,
M. Becker,
E. Dorando,
R. L. Pacheco,
A. L. C. Martimbianco,
R. Riera,
N. Skoetz and
M. Stegemann,
"Colchicine for the treatment of COVID‐19",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD015045,
2021.
| DOI: | 10.1002/14651858.CD015045 |
M. Ochs,
S. Timm,
S. Elezkurtaj,
D. Horst,
J. Meinhardt and
e. a. Heppner,
"Collapse induration of alveoli is an ultrastructural finding in a COVID-19 patient",
Eur Respir J,
vol. 57,
2021.
| DOI: | 10.1183/13993003.02311-2020 |
K. Herbst,
M. Meurer,
D. Kirrmaier and
others,
"Colorimetric RT-LAMP and LAMP-sequencing for Detecting SARS-CoV-2 RNA in Clinical Samples",
BIO-Protocols,
vol. 11,
no. 6,
2021.
| DOI: | 10.21769/BioProtoc.3964 |
| Datei: | https://doi.org/10.21769/BioProtoc.3964 |
L. Brunotte,
S. Zheng,
A. Mecate-Zambrano,
J. Tang,
S. Ludwig and
e. a. Rescher,
"Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro",
Pharmaceutics,
vol. 13,
2021.
A. Müller,
F. Engler,
D. Schütze,
P. Nohl-Deryk and
C. Güthlin,
"Communication experience by secure instant messaging during the Covid-19 pandemic for general practitioners and public health workers – a qualitative analysis",
Doc21dkvf051,
2021.
| DOI: | 10.3205/21dkvf051 |
A. Osterman,
M. Iglhaut,
A. Lehner and
et al,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Med Microbiol Immunol,
vol. 210,
2021.
| DOI: | 10.1007/s00430-021-00719-0 |
A. Osterman,
M. Iglhaut,
A. Lehner,
P. Späth,
M. Stern,
H. Autenrieth,
M. Muenchhoff,
A. Graf,
S. Krebs,
H. Blum,
A. Baiker,
N. Grzimek-Koschewa,
U. Protzer,
L. Kaderali,
H. Baldauf and
O. T. Keppler,
"Comparison of four commercial, automated antigen tests to detect SARS-CoV-2 variants of concern",
Medical microbiology and immunology,
vol. 210,
no. 5-6,
pp. 263—275,
2021.
Abstract:
A versatile portfolio of diagnostic tests is essential for the containment of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Besides nucleic acid-based test systems and point-of-care (POCT) antigen (Ag) tests, quantitative, laboratory-based nucleocapsid Ag tests for SARS-CoV-2 have recently been launched. Here, we evaluated four commercial Ag tests on automated platforms and one POCT to detect SARS-CoV-2. We evaluated PCR-positive (n = 107) and PCR-negative (n = 303) respiratory swabs from asymptomatic and symptomatic patients at the end of the second pandemic wave in Germany (February-March 2021) as well as clinical isolates EU1 (B.1.117), variant of concern (VOC) Alpha (B.1.1.7) or Beta (B.1.351), which had been expanded in a biosafety level 3 laboratory. The specificities of automated SARS-CoV-2 Ag tests ranged between 97.0 and 99.7% (Lumipulse G SARS-CoV-2 Ag (Fujirebio): 97.03%, Elecsys SARS-CoV-2 Ag (Roche Diagnostics): 97.69%; LIAISONćircledR SARS-CoV-2 Ag (Diasorin) and SARS-CoV-2 Ag ELISA (Euroimmun): 99.67%). In this study cohort of hospitalized patients, the clinical sensitivities of tests were low, ranging from 17.76 to 52.34%, and analytical sensitivities ranged from 420,000 to 25,000,000 Geq/ml. In comparison, the detection limit of the Roche Rapid Ag Test (RAT) was 9,300,000 Geq/ml, detecting 23.58% of respiratory samples. Receiver-operating-characteristics (ROCs) and Youden's index analyses were performed to further characterize the assays' overall performance and determine optimal assay cutoffs for sensitivity and specificity. VOCs carrying up to four amino acid mutations in nucleocapsid were detected by all five assays with characteristics comparable to non-VOCs. In summary, automated, quantitative SARS-CoV-2 Ag tests show variable performance and are not necessarily superior to a standard POCT. The efficacy of any alternative testing strategies to complement nucleic acid-based assays must be carefully evaluated by independent laboratories prior to widespread implementation.
| DOI: | 10.1007/s00430-021-00719-0 |
Abstract:
A versatile portfolio of diagnostic tests is essential for the containment of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Besides nucleic acid-based test systems and point-of-care (POCT) antigen (Ag) tests, quantitative, laboratory-based nucleocapsid Ag tests for SARS-CoV-2 have recently been launched. Here, we evaluated four commercial Ag tests on automated platforms and one POCT to detect SARS-CoV-2. We evaluated PCR-positive (n = 107) and PCR-negative (n = 303) respiratory swabs from asymptomatic and symptomatic patients at the end of the second pandemic wave in Germany (February-March 2021) as well as clinical isolates EU1 (B.1.117), variant of concern (VOC) Alpha (B.1.1.7) or Beta (B.1.351), which had been expanded in a biosafety level 3 laboratory. The specificities of automated SARS-CoV-2 Ag tests ranged between 97.0 and 99.7% (Lumipulse G SARS-CoV-2 Ag (Fujirebio): 97.03%, Elecsys SARS-CoV-2 Ag (Roche Diagnostics): 97.69%; LIAISONćircledR SARS-CoV-2 Ag (Diasorin) and SARS-CoV-2 Ag ELISA (Euroimmun): 99.67%). In this study cohort of hospitalized patients, the clinical sensitivities of tests were low, ranging from 17.76 to 52.34%, and analytical sensitivities ranged from 420,000 to 25,000,000 Geq/ml. In comparison, the detection limit of the Roche Rapid Ag Test (RAT) was 9,300,000 Geq/ml, detecting 23.58% of respiratory samples. Receiver-operating-characteristics (ROCs) and Youden's index analyses were performed to further characterize the assays' overall performance and determine optimal assay cutoffs for sensitivity and specificity. VOCs carrying up to four amino acid mutations in nucleocapsid were detected by all five assays with characteristics comparable to non-VOCs. In summary, automated, quantitative SARS-CoV-2 Ag tests show variable performance and are not necessarily superior to a standard POCT. The efficacy of any alternative testing strategies to complement nucleic acid-based assays must be carefully evaluated by independent laboratories prior to widespread implementation.
P. Georg and
et al,
"Complement activation induces excessive T cell cytotoxicity in severe COVID-19",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.040 |
P. Georg,
R. Astaburuaga-García,
L. Bonaguro and
et al,
"Complement activation induces excessive T cell cytotoxicity in severe COVID-19",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.040 |
B. Föh,
M. Borsche,
A. Balck and
et al,
"Complications of nasal and pharyngeal swabs – a relevant challenge of the COVID-19 pandemic?",
Eur Respir J,
2021.
| DOI: | 10.1183/13993003.04004-2020 |
V. Piechotta,
C. Iannizzi,
K. L. Chai,
S. J. Valk,
C. Kimber,
E. Dorando,
I. Monsef,
E. M. Wood,
A. A. Lamikanra,
D. J. Roberts,
Z. McQuilten,
C. So-Osman,
L. J. Estcourt and
N. Skoetz,
"Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD013600,
2021.
| DOI: | 10.1002/14651858.CD013600.pub4 |
F. Beierle and
et al,
"Corona Health—A Study- and Sensor-Based Mobile App Platform Exploring Aspects of the COVID-19 Pandemic",
Int J Environ Res Public Health,
vol. 18,
pp. 7395,
2021.
| DOI: | 10.3390/ijerph18147395 |
S. Steudte-Schmiedgen,
L. Stieler,
Y. Erim,
E. Morawa,
F. Geiser,
P. Beschoner,
L. Jerg-Bretzke,
C. Albus,
N. Hiebel and
K. Weidner,
"Correlates and Predictors of PTSD Symptoms Among Healthcare Workers During the COVID-19 Pandemic: Results of the egePan-VOICE Study",
Frontiers in Psychiatry,
vol. 12,
2021.
| DOI: | 10.3389/fpsyt.2021.686667 |
| Datei: | https://doi.org/10.3389/fpsyt.2021.686667 |
A. Ebigbo,
C. Römmele,
C. Bartenschlager and
et al,
"Cost-effectiveness analysis of SARS-CoV-2 infection prevention strategies including pre-endoscopic virus testing and use of high risk personal protective equipment",
Endoscopy,
vol. 53,
no. 2,
2021.
| DOI: | 10.1055/a-1294-0427 |
M. Baumann,
"COVID-19 and mental health in children and adolescents: a diagnostic panel to map psycho-social consequences in the pandemic context",
Discov Ment Health,
vol. 1,
no. 1,
pp. 2,
2021.
| DOI: | 10.1007/s44192-021-00002-x |
N. Ritschel,
H. Radbruch,
C. Herden,
N. Schneider,
C. Dittmayer and
e. a. Franz,
"COVID-19 and the central and peripheral nervous system",
Pathologe,
vol. 42,
pp. 172—182,
2021.
| DOI: | 10.1007/s00292-021-00923-w |
P. Adhikary,
Q. Ul Ain,
A. Hocke and
S. Hedtrich,
"COVID-19 highlights the model dilemma in biomedical research",
Nat Rev Mater,
pp. 1—3,
2021.
W. Roth and
P. Boor,
"COVID-19 im Spiegel der Pathologie [COVID-19 in the mirror of pathology]",
Pathologe,
vol. 42,
no. 2,
pp. 147-148,
2021.
E. Gaitzsch and
et al,
"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma",
HemaSphere,
vol. 5,
pp. e603,
2021.
| DOI: | 10.1097/HS9.0000000000000603 |
E. Gaitzsch,
V. Passerini,
E. Khatamzas and
et al,
"COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma",
Hemasphere,
vol. 5,
no. 7,
2021.
| DOI: | 10.1097/HS9.000000000000060 |
S. Heinemann,
A. Bludau,
H. Kaba and
et al,
"COVID-19 surveillance and testing strategies für patiens in German hospitals – results from a cross-sectional study",
DGHM,
2021.
| Datei: | https://www.egms.de/static/de/journals/dgkh/2021-16/dgkh000402.shtml |
A. Bludau,
M. Anton,
S. Heinemann and
et al,
"COVID-19 vaccination and immunization surveillance for employees in German hospitals – results from a cross-sectional study",
DGHM,
2021.
| Datei: |  https://www.dghm-kongress.de/fileadmin/congress/media/dghm2021/pdf/DGHM_2021_digital_Programme_booklet.pdf |
R. Tanacli,
P. Doeblin,
C. Götze,
V. Zieschang,
A. Faragli,
C. Stehning,
G. Korosoglou,
J. Erley,
J. Weiss,
A. Berger and
others,
"COVID-19 vs. Classical Myocarditis Associated Myocardial Injury Evaluated by Cardiac Magnetic Resonance and Endomyocardial Biopsy",
Front Cardiovasc Med,
vol. 8,
pp. 737257,
2021.
| DOI: | 10.3389/fcvm.2021.737257 |
K. Amann,
P. Boor,
T. Wiech,
J. Singh,
E. Vonbrunn,
A. Knöll,
M. Hermann,
M. Büttner-Herold,
C. Daniel and
A. Hartmann,
"COVID-19-Auswirkungen auf die Niere [COVID-19 effects on the kidney]",
Pathologe,
vol. 42,
no. 2,
pp. 183-187,
2021.
C. Seeber,
M. Popp,
J. J. Meerpohl and
et al,
"COVID-19-Pandemie: Präferenzen und Barrieren für die Disseminierung von Evidenzsynthesen",
Anaesthesist,
2021.
| DOI: | 10.1007/s00101-021-01037-z |
K. Polotzek,
A. Karch,
J. Karschau,
M. Wagner,
B. Lünsmann,
M. Menk,
C. Römmele and
J. Schmitt,
"COVID-19-Pandemie: Regionale Steuerung der Patienten",
Dtsch Arztebl International,
vol. 118,
no. 3,
pp. 84—,
2021.
N. Ritschel,
H. Radbruch,
C. Herden,
N. Schneider and
et al,
"COVID-19: Auswirkungen auf das zentrale und periphere Nervensystem",
Pathologe,
vol. 42,
pp. 172-182,
Mä.
2021.
| DOI: | https://doi.org/10.1007/s00292-021-00924-x |
M. Ackermann,
C. Werlein,
F. Länger,
M. P. Kühnel and
D. D. Jonigk,
"COVID-19: Auswirkungen auf Lunge und Herz [COVID-19: effects on the lungs and heart]",
Pathologe,
vol. 42,
no. 2,
pp. 164-171,
2021.
L. Loyal,
J. Braun,
L. Henze,
B. Kruse,
M. Dingeldey and
e. a. Reimer,
"Cross-reactive CD4(+) T cells enhance SARS-CoV-2 immune responses upon infection and vaccination",
Science,
2021.
L. Loyal and
et al,
"Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination",
Science (New York, N.Y.),
2021.
| DOI: | 10.1126/science.abh1823 |
M. Metzendorf,
"Das Cochrane COVID-19 Studienregister – eine studienbasierte, strukturierte Datenbank zur effizienten Identifizierung wissenschaftlicher Evidenz",
GMS Med Bibl Inf,
vol. 21,
no. 1-2,
pp. Doc09,
Sep.
2021.
| DOI: | 10.3205/mbi000498 |
C. Edler,
A. Klein,
A. Schröder,
J. Sperhake and
B. Ondruschka,
"Deaths associated with newly launched SARS-CoV-2 vaccination (Comirnaty®)",
Leg Med (Tokyo),
vol. 51,
pp. 101895,
Jul.
2021.
| DOI: | 10.1016/j.legalmed.2021.101895 |